Meta content: Nova Eye Medical Ltd is an ASX-listed company (ticker: EYE). This article provides detailed insights into the company's operations, market position, and Investment thesis.

Nova Eye Medical Ltd (ASX:EYE) is an Australian ophthalmic device maker that has spent years chasing scale in the United States glaucoma market. On the evidence of its latest figures, the effort is starting to translate into both growth and improving profitability.

The company's flagship iTrack Advance device has been the engine of a fourth straight year of sales growth above 25 per cent, and the group has finally reached positive Earnings before interest, tax, Depreciation and Amortisation in the second half. For a small-cap medical technology business, moving toward breakeven is a meaningful milestone. Here is what has been reported and why it counts.

What Just Happened?

In its June 2026 quarter update, Nova Eye reported full-year FY26 sales of about 23.7 million US dollars, equivalent to roughly 35 million Australian dollars, up 26 per cent year-on-year. That marked the fourth consecutive year of sales growth exceeding 25 per cent. Crucially, the company delivered positive EBITDA of about 0.14 million US dollars in the second half, ahead of its earlier breakeven guidance, and cut its full-year EBITDA loss to about 1.3 million US dollars, an improvement of some 2.2 million US dollars on the prior year.

The United States did the heavy lifting. US sales reached about 18.6 million US dollars, up 30 per cent, while sales excluding China rose 29 per cent to about 22.7 million US dollars. Germany grew 5 per cent to around 2.0 million US dollars and the rest of the world rose 47 per cent. Management estimated US penetration at roughly 4 per cent of the 30,000 to 35,000 monthly glaucoma surgical procedures. At 30 June 2026 the company held about 1.0 million Australian dollars in cash plus 2.7 million dollars in unused Debt facilities. Guidance for FY27 points to sales excluding China of 26 to 31 million US dollars, with a target of positive EBITDA.

Why It Matters

The shift to positive second-half EBITDA is the headline change. For years, small medical device companies like Nova Eye have grown Revenue while burning cash. Reaching a point where the core Business can cover its costs, even briefly, reduces the pressure to raise Equity and dilute shareholders.

The quality of the growth also matters. Sales are being driven by the United States, the largest and most valuable glaucoma market, and by direct selling rather than lower-margin distribution. With penetration estimated at only around 4 per cent of monthly procedures, there is a long runway if the device continues to win surgeon adoption.

The cash position is the counterweight. With about 1.0 million dollars in cash at year-end plus modest undrawn facilities, the Balance Sheet is thin, which is why reaching profitability and securing non-dilutive Working Capital funding are so important to the story.

The Bigger Picture

Nova Eye Medical designs and sells devices for the treatment of glaucoma and retinal disease. Its lead product, iTrack Advance, is a minimally invasive glaucoma surgery device used to open the eye's natural drainage pathway, and it holds approvals in major markets including the United States. The company also has an earlier-stage retinal technology and is evaluating its iTrack microcatheter as a potential platform for drug delivery, working with possible partners.

The commercial model centres on building a direct sales presence in key markets, led by the United States and Germany, while using distributors elsewhere. Favourable US Medicare reimbursement settings for 2026 have supported demand, and October 2025 was cited as a record revenue month during the year.

For a new reader, the core idea is simple. Nova Eye is trying to grow a differentiated glaucoma device into a mainstream surgical option, capturing share in a large and underpenetrated market while pushing the overall business toward sustainable profit.

What Could Drive the Shares Next?

Delivery against FY27 guidance is the central catalyst. Management has guided to sales excluding China of 26 to 31 million US dollars and is targeting positive EBITDA for the full year. Evidence in quarterly updates that the company is tracking toward those figures would support the shares.

Continued US momentum is the second driver. Rising penetration of iTrack Advance among American glaucoma surgeons, helped by stable reimbursement, is the clearest path to growth. Any progress on the microcatheter drug-delivery evaluation, including a partnership, could add a new dimension.

Non-dilutive funding is a further watch point. The company has pointed to a working capital Facility backed by receivables and tangible assets, and strengthening the balance sheet without issuing new shares would be well received.

Risks Investors Should Watch

Cash is the most immediate risk. With around 1.0 million dollars on hand at 30 June 2026 and limited undrawn facilities, any stumble in sales or a delay in reaching sustained profit could revive funding pressure and the threat of dilution.

Reimbursement and regulation are ever-present in medical devices. A change to US Medicare rates for glaucoma procedures, or shifts in approvals, could alter Demand quickly. Competition from larger device makers in the minimally invasive glaucoma surgery space is also intense.

Execution and concentration add to the picture. The company is heavily reliant on the United States and on a single flagship product, so a slowdown in surgeon adoption would weigh on the whole result. China remains excluded from guidance, reflecting uncertainty there, and small-cap Liquidity means the shares can move sharply on modest volume.

Bottom Line

Nova Eye Medical has reached an encouraging point in its long push into the United States glaucoma market. A fourth consecutive year of sales growth above 25 per cent, powered by a 30 per cent lift in US revenue, has been paired with a first taste of positive second-half EBITDA and a smaller full-year loss. That combination of growth and improving profitability is exactly what a maturing device company needs to show.

The catch is a thin balance sheet, which makes hitting FY27 guidance and reaching sustained profit essential rather than optional. If iTrack Advance keeps winning surgeons and the group converts growth into cash, the investment case strengthens. For now, the Nova Eye ASX shares reflect a business that has narrowed the gap to profitability but still has work to do.